Description: Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
Home Page: www.abeonatherapeutics.com
0H7R Technical Analysis
6555 Carnegie Avenue
Cleveland,
OH
44103
United States
Phone:
646 813 4701
Officers
| Name | Title |
|---|---|
| Dr. Vishwas Seshadri M.B.A., Ph.D. | President, CEO & Director |
| Mr. Brian Kevany Ph.D. | Senior VP, CTO & CSO |
| Mr. Gregory Gin | Vice President of Investor Relations & Corporate Communications |
| Ms. Alison Hardgrove | Chief People Officer |
| Mr. Jon Voss | VP & Head of Quality |
| Dr. Madhav Vasanthavada M.B.A., Ph.D. | Senior VP, Chief Commercial Officer & Head of Business Development |
| Mr. Carl Denny | Senior Vice President of Regulatory Affairs |
Exchange: LSE
Country: GB : United Kingdom of Great Britain and Northern Ireland
Currency: US Dollar ($)
| GIC Sector: | Industrials |
|---|---|
| GIC Group: | Commercial & Professional Services |
| GIC Industry: | Commercial Services & Supplies |
| GIC Sub-Industry: | Environmental & Facilities Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 39.3514 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 84 |